Detalhe da pesquisa
1.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2040-2051, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280635
2.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914866
3.
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Lancet Oncol
; 18(5): 623-630, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28291584
4.
Emerging treatment for advanced lung cancer with EGFR mutation.
Expert Opin Emerg Drugs
; 20(4): 597-612, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26153235
5.
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
JTO Clin Res Rep
; 4(1): 100431, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36793385
6.
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.
Immunotherapy
; 14(5): 295-307, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073727
7.
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Sci Rep
; 11(1): 9222, 2021 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33911121
8.
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.
JCO Clin Cancer Inform
; 5: 56-65, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33439727
9.
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Lung Cancer
; 155: 175-182, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839603
10.
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
Lung Cancer
; 154: 99-104, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33636454
11.
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.
JTO Clin Res Rep
; 2(8): 100205, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590048
12.
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
J Thorac Oncol
; 16(11): 1883-1892, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34265431
13.
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
J Thorac Oncol
; 16(10): 1718-1732, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34048946
14.
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
J Clin Oncol
; 39(21): 2327-2338, 2021 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33513313
15.
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
J Thorac Oncol
; 16(1): 162-168, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33069888
16.
KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.
Ann Surg Oncol
; 17(4): 1168-76, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19936839
17.
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
HPB (Oxford)
; 12(3): 204-10, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20590888
18.
Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Clin Lung Cancer
; 21(5): e445-e455, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32376116
19.
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Cancers (Basel)
; 12(12)2020 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33291810
20.
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
J Thorac Oncol
; 15(10): 1657-1669, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32599071